This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Carbamazepine Treatment of Cocaine Dependence - 1

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT00000242
First received: September 20, 1999
Last updated: April 6, 2017
Last verified: July 1996
  Purpose
The purpose of this study is to compare the efficacy of carbamazepine in treatment of cocaine-dependence in patients with affective disorders.

Condition Intervention Phase
Cocaine-Related Disorders Substance-Related Disorders Drug: Carbamazepine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Carbamazepine Treatment of Cocaine Dependence

Resource links provided by NLM:


Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • Severity addiction
  • Amount of drug use
  • Affective stability
  • Medication compliance

Estimated Enrollment: 0
Actual Study Start Date: October 1, 1992
Study Completion Date: January 25, 1997
Primary Completion Date: January 25, 1997 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000242

Locations
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425 742
Sponsors and Collaborators
Medical University of South Carolina
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Kathleen Brady, Ph.D. Medical University of South Carolina
  More Information

Publications:
(1) Brady KT et. al. Features of cocaine dependence with concurrent alcohol abuse. Drug and Alcohol Depend. 1995, 39(1):69-71. (2) Brady KT et. al. Personality disorder and assault history in substance-dependent individuals. Am J on Addictions. 1995, 4(4):306-312. (3) Dansky et. al. Use of self-report measures of crime-related posttraumatic stress disorder with substance use disordered patients. Journal of Substance Abuse Treatment. (in press). (4) Sonne an Presentation at CPDD meeting, 1996.

Responsible Party: Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT00000242     History of Changes
Other Study ID Numbers: NIDA-07761-1
R29DA007761 ( US NIH Grant/Contract Award Number )
R29-07761-1
Study First Received: September 20, 1999
Last Updated: April 6, 2017

Keywords provided by Medical University of South Carolina:
Cocaine
Substance Abuse

Additional relevant MeSH terms:
Disease
Cocaine-Related Disorders
Substance-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Carbamazepine
Cocaine
Anticonvulsants
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action
Anesthetics, Local
Anesthetics
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on June 23, 2017